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Abstract
Objectives Map the current landscape of commercially available artificial intelligence (AI) software for radiology and review the
availability of their scientific evidence.
Methods We created an online overview of CE-marked AI software products for clinical radiology based on vendor-supplied
product specifications (www.aiforradiology.com). Characteristics such as modality, subspeciality, main task, regulatory
information, deployment, and pricing model were retrieved. We conducted an extensive literature search on the available
scientific evidence of these products. Articles were classified according to a hierarchical model of efficacy.
Results The overview included 100 CE-marked AI products from 54 different vendors. For 64/100 products, there was no peer-
reviewed evidence of its efficacy. We observed a large heterogeneity in deployment methods, pricing models, and regulatory
classes. The evidence of the remaining 36/100 products comprised 237 papers that predominantly (65%) focused on diagnostic
accuracy (efficacy level 2). From the 100 products, 18 had evidence that regarded level 3 or higher, validating the (potential)
impact on diagnostic thinking, patient outcome, or costs. Half of the available evidence (116/237) were independent and not
(co-)funded or (co-)authored by the vendor.
Conclusions Even though the commercial supply of AI software in radiology already holds 100 CE-marked products, we
conclude that the sector is still in its infancy. For 64/100 products, peer-reviewed evidence on its efficacy is lacking. Only 18/
100 AI products have demonstrated (potential) clinical impact.
Key Points
• Artificial intelligence in radiology is still in its infancy even though already 100 CE-marked AI products are commercially
available.
• Only 36 out of 100 products have peer-reviewed evidence of which most studies demonstrate lower levels of efficacy.
• There is a wide variety in deployment strategies, pricing models, and CE marking class of AI products for radiology.
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Abbreviations
AI Artificial intelligence
CE mark European Conformity Marking
ECR European Congress of Radiology
FDA Food and Drug Administration
MSK Musculoskeletal
PMA Premarket Approval
RSNA Radiological Society of North America
Introduction
The number of artificial intelligence (AI) products for radiol-
ogy has rapidly expanded over the past years. The number of
AI exhibitors at the yearlymeeting of the Radiological Society
of North America (RSNA) and European Congress of
Radiology (ECR) has almost tripled from 2017 to 2019 [1,
2]. Even though the supply of AI software for radiology is vast
and many radiologists seem willing to adopt and adapt AI
tools, clinical implementation remains limited [3–5].
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It has been shown that the extent in which research algorithms
have been validated varies widely [6–8]. Only 6% of the recent
papers onmedical deep learning algorithms included a validation
on independent external data [6]. The available evidence for
commercially available AI software has not been studied yet.
We focus on commercial products specifically as these are the
products that are currently available for clinical use.
With this study, we aim to increase market transparency
and contribute to the safe and well-considered implementation
of AI software in radiology departments. We present an over-
view of commercially available (CE-marked) AI products for
radiology. For each of these products, we collected and
reviewed the scientific evidence demonstrating the efficacy
of the AI software.
Materials and methods
Product overview
Artificial intelligence is defined by the ISO/IEC TR
24028:2020 as the “capability of an engineered system to
acquire, process and apply knowledge and skills” [9].
Within this scope, we focus on image analysis products which
use techniques such as machine learning and deep learning.
To establish an overview of AI software products, exhibitor
lists from RSNA and ECR and marketplace offerings were
reviewed. Also, news sources were monitored for the appear-
ance of new vendors, products, or certifications. In Europe,
the CE mark is a prerequisite for medical devices to be
allowed on the market; therefore, CE marking of the product
by April 2020 was a requirement for inclusion. Also, the
product had to be vendor neutral and aid the radiologist in
image interpretation in clinical practice. We excluded soft-
ware used for dictation or image reconstruction at the source.
Some vendors offer “suites” incorporating different software
components performing different tasks, while other vendors
market these components as separate products. To perform a
balanced evaluation, we considered suite components as sep-
arate products. As the market is fast moving, we maintain an
overview of products on www.aiforradiology.com.
Discrepancies between the included products in this article
and the Web resource may be caused by updates of the
website, refusal of companies to appear on the website, and
stricter inclusion criteria for this review.
All vendors were contacted to verify the collected informa-
tion and supplement the product specifications. We retrieved
information about the organ-based subspeciality, modality,
and main task of the product. Also, the date to market, method
of deployment, and pricing model were gathered. The CE
status was verified by collecting the CE certificates or
Declaration of Conformity of the vendors; a public database
does not exist yet (EUDAMED is planned for 2021) [10].
Also, the American FDA (Food and Drug Administration)
approval status was gathered and confirmed with the public
FDA database [11]. CE and FDA status reported in this study
reflect the status in September 2020. For the most recent in-
formation, visit www.aiforradiology.com.
Evidence
Scientific evidence for the efficacy of the AI products was
gathered in two ways. First, PubMed was systematically
searched by vendor and product name for peer-reviewed arti-
cles published between Jan 1, 2015, and May 18, 2020.
Queries are provided in the supplementary materials,
Table S1. Secondly, a manual search was performed by
inspecting the vendor’s websites for listings of papers and
requesting vendors to provide peer-reviewed papers. No date
restriction was applied for the manual search.
Included articles were original, peer-reviewed, and in English,
and aimed to demonstrate the efficacy of the AI software. Papers
were included when the product name (including known former
names) and/or company name were mentioned, the tool was
applied on in vivo human data, and efficacy of the product was
reported on an independent dataset (data on which the algorithm
was not trained) [12]. Letters, commentaries, reviews, study pro-
tocols, white papers, and case reports were excluded.
Papers were assessed by two of the authors who indepen-
dently screened the title, abstracts, and full paper for inclusion
criteria. Cases of disagreement were resolved by the reviewers
in a consensus meeting.
Hierarchical model of efficacy
We propose an adapted hierarchical model of efficacy to catego-
rize the papers with respect to the type of validation addressed.
Originally, thismodelwas developed by Fryback and Thornbury
in 1991 as a structure to assess the contribution of diagnostic
imaging to patient management [13]. It comprises six levels
assessing an innovation from its technical efficacy—level 1
(does it do what it is supposed to do)—up until societal
efficacy—level 6 (how do the costs and benefits compare). We
have adapted the definitions and split level 1 into two subtypes to
better accommodate the appraisal of scientific evidence regard-
ing the contribution of AI software to the diagnostic imaging
process. The adapted definition of each level is given in Table 1.
Analysis
Products were categorized according to the aimed
subspeciality, modality, main task, CE marking, FDA clear-
ance, deployment method, and pricing model. We calculated
the mean time between the founding of the company and
bringing their first AI product to the market, excluding com-
panies that were founded before 2005.
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We report the available scientific evidence and the level of
efficacy the papers addressed. Multiple levels could be
assessed by a single paper. For each article, we reviewed the
author list, funding source, and disclosures to categorize the
publication as vendor independent or not. Data used in the
included papers was categorized for the number of centers,
countries, and acquisition machine manufacturers it originated
from. We aggregated this information per product to give
insights in the total number of centers, countries, and manu-
facturers addressed in the total evidence of that product.
Results
Product overview
The product search resulted in 100 AI solutions that are CE
marked and commercially available in Europe. From 74 out of
the 100 products, product information was provided by the
vendors. The remaining products were analyzed using public
information only.
Results in Fig. 1 show that available AI software mostly
address neuroradiology (38) and chest radiology (31),
followed by breast (12) and musculoskeletal (11) radiology.
Regarding the modalities, products are distributed over CT
(37), MR (25), and X-ray (22). The main tasks performed by
the software are quantification tasks (33), such as region seg-
mentation or performing automated measurements. Out of the
53 vendors, 18 provide multiple products, of which 7 address
multiple organ-based subspecialities.
Out of the 100 CE-marked products, 51 also have FDA
clearance as can be seen in Fig. 2. QVCAD by QView
Medical and ClearRead Xray - Detect by Riverain
Technologies have the most stringent premarket approval
Table 1 Hierarchical model of efficacy to assess the contribution of AI
software to the diagnostic imaging process, adapted from Fryback and
Thornbury (1991) [13]
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Level 1t level 1, technical; Level 1c level 1, clinical
Fig. 1 Characteristics of 100 CE-marked AI products based on organ-
based subspeciality, modality, and main functionality. MSK,
musculoskeletal
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(PMA), class III. All other products have class II clearance via
the 510(k) pathway, except for Viz.ai which received class II
clearance via De Novo premarket review pathway.
Regarding the CE mark, we observe a spread over risk class
I (32%) and class IIa (53%). For the remaining 15 products, we
did not receive the information from the vendor and could not
find sufficient public information to determine the class.
A majority of the vendors offer their products with multiple
options regarding the deployment strategy and pricing model as
demonstrated in Fig. 2. Local installations (n = 67) and cloud-
based (n = 70) offerings are similarly represented of which 54
products permit both. Subscription/licensemodels aremore prev-
alent (n = 56) than the pay-per-use pricing model (n = 28), but a
large number of products (n = 22) are offered with both models.
From the 94 products of which we retrieved the date to
market, 64 were launched between 2018 and May 2020. The
mean time to market from foundation of the company to the
first AI product on the market was 3 years and 11months. The
founding date of the company as well as the market release
date and publications for each product are shown in Fig. 3.
For complete specifications of individual products, we re-
fer to our public online database on www.aiforradiology.com
that is regularly updated.
Evidence
The search strategies on PubMed yielded a total of 791 papers,
fromwhich 175met the inclusion criteria.Manual search added
62 additional papers, resulting in a total of 237 included peer-
reviewed articles. The flowchart of the inclusion is displayed in
Figure S1 in the supplementary materials. An article could ap-
pear multiple times in the overview when it addressed more
than one AI product (n = 21). Search queries and the resulting
hits are provided in Table S1 of the supplementary materials.
For 64 of 100 included commercially available AI prod-
ucts, no scientific peer-reviewed papers via PubMed or man-
ual search were retrieved as can be seen in Fig. 4. Figure 5
shows the evidence on the efficacy of the other 36 products.
From all papers, 65% (153/237) evaluated the diagnostic
accuracy efficacy (level 2), demonstrating the stand-alone per-
formance of the product; 27% (63/237) comprised studies
demonstrating either clinical or technical feasibility of the
product (level 1t and 1c). Studies addressing efficacy levels
3 or higher validate aspects of the (potential) clinical impact of
the AI software. From all studies, 27% (64/237), involving 18
products, evaluated the efficacy on level 3 or higher.
Almost half of the studies (116/237) were performed inde-
pendently from the vendor. A vast majority of studies (192/
237) were retrospective in design. Multicenter data was used
in only 30% (71/237) of the studies. Data inclusion covered
multiple countries in 15% (35/237) of the papers and data
were acquired with scanners from multiple manufacturers in
25% (59/237) of the included studies. When aggregating all
studies per product, a majority of the products with evidence
on the efficacy were validated with data frommultiple scanner
manufacturers, multiple centers, and multiple countries as
demonstrated in Fig. 4.
A summary of the article characteristics per product is pro-
vided in the supplementary materials Table S2.
Discussion
The aim of this study was to increase transparency in the
field of commercial AI software in radiology and its scien-
tific evidence. Our results demonstrate that despite the vast
amount of offerings, the market is still in its infancy. Only
36 out of the 100 evaluated CE-marked products had peer-
reviewed evidence on the efficacy of the AI software. If
evidence was present, the focus was mostly on technical
and clinical feasibility (27%) and stand-alone performance
(65%) and few studies (also) addressed the clinical impact
(27%) of the software. Deployment and pricing strategies
have not yet converged to a preferred standard and most
vendors offer multiple options. The fact that two-thirds of
the products were brought to market in the past 2 years
(January 2018–April 2020) may be an explanation for this.
Even though the 100 products evaluated in this study are CE
Fig. 2 Distribution of CE class, FDA class, pricing model, and deployment strategies of 100 CE-marked AI products. CE, European Conformity
Marking; FDA, Food and Drug Administration
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Fig. 3 Visualization of the
timeline for the one hundred CE-
marked AI products. Yellow
circles denote the year the
company was founded, red circles
the year the product was brought
to market, and blue circles
provide the date of peer-reviewed
papers. The larger the circle, the
more papers were published in
that year. Product specifications
were not verified by the vendor
when the product is listed in gray
text
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marked and commercially available in Europe, for most
products we await to discover the impact they have in clin-
ical practice.
Supply
A majority of solutions evaluated here offer an AI product to
perform a specific task. In the area of stroke and oncology, we
observe more “suites” aiming to address the whole diagnostic
path. Only 7 vendors address multiple organ-based
subspecialities with their products. For radiologists and their
departments, this means that they have to deal with multiple
vendors to supply their AI need for the different tasks and
specialties. This implies an overhead of sales, contracts, tech-
nical integration procedures, training, and evaluation. The rise
of marketplaces offered by scanner manufacturers, PACS
companies, and new parties that aim to form the middleman
may mitigate this problem when AI in radiology becomes
more widely used.
Regulatory approval
Some AI product overviews have previously been published
[14, 15]. However, we are the first to specifically consider AI
software as a medical device that is on the European market
today (CEmarked). We believe this is the most relevant group
of products to study for two reasons. First, these are products
that are available for clinical use and should have passed the
initial research and development phase. Second, the regulato-
ry approval system of medical devices in Europe is not trans-
parent. There is no public database available to verify certifi-
cation or the clinical validation on which the certification was
based, such as the American counterpart, FDA, does offer [10,
11]. In addition, vendors often do not clearly state on their
website if their product has a CE mark, and if so which class.
Through requesting this information, we aim to increase trans-
parency of the market.
Our results revealed that almost all products are either cer-
tified as class I or class IIa under the Medical Device
Directory. The classes are related to the risk of the product:
Fig. 4 Peer-reviewed articles were present for 36 out of the 100
commercially available AI products. For these 36 products, the three
pie charts on the right demonstrate the characteristics of the validation
data when aggregating all included papers per product (i.e., the number of
scanner manufacturers, centers, and countries)
Fig. 5 The levels of efficacy of
the included papers. The search
strategy yielded 239 peer-
reviewed publications on the
efficacy of 36 out of 100
commercially available AI
products. A single paper could
address multiple levels
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class I being a low risk and class III a very high-risk medical
device. Noteworthy is that similar products may be certified
under different classes. We observe this, for example, among
products aimed at large vessel occlusion detection, chest X-
ray abnormality detection, or brain region quantification.
Whereas a class I CE mark is obtained through self-certifica-
tion, class II requires an external audit by a notified body,
which is a more elaborate process that includes the assessment
of, among other things, the validation results. The Medical
Device Regulation that will replace the current Medical
Device Directory as of May 2021 may change this discrepan-
cy over classes and necessary validation as it is expected that
most AI software products inmedical imagingwill become IIa
or even IIb. It remains to be seen if this will also affect the
amount of peer-reviewed evidence on the AI software.
Evidence
In this study, we reported the available peer-reviewed evi-
dence categorized by level of efficacy (Table 1). We proposed
a hierarchical model of efficacy and this may raise the ques-
tion what level is needed to prove efficacy of the product. We
believe there is no general answer to this question: it is depen-
dent on the product and its intended use. Demonstrating
higher levels of efficacy may be necessary when, e.g., opting
for health insurance reimbursement. However, in case the al-
gorithm performs a measurement task that a radiologist would
otherwise do, demonstrating accuracy (level 2) may be suffi-
cient and higher level validation maymerely lead to high costs
for clinical studies, thus driving up the price of the software.
Limitations
We are aware that the definition of AI or what is part of
clinical radiological practice is not trivial, and therefore our
product inclusion criteria are somewhat debatable. For exam-
ple, products for analysis of cardiac ultrasound were excluded
from this study as this is often (but not always) part of the
cardiology department. We believe this study provides a gen-
eral overview of what the current state of AI in radiology
entails.
Unfortunately, some vendors did not respond to our request
to provide information or decided to withhold some informa-
tion. Therefore, for some product information on the CE class,
distribution model and pricing strategy is incomplete. We
completed the missing information with public data where
possible.
Future perspective
The development of EUDAMED may be an important step
forward to more transparency in the medical device industry.
We demonstrated that publicly available peer-reviewed
evidence on the efficacy of AI products is often lacking.
Preferably, the data and validations by which the AI products
are CE marked would be included in the public database.
The finding that most products were brought tomarket in the
past 2 years demonstrates that this is a dynamic and evolving
market. This study provides a snapshot of the AI landscape in
clinical radiology. To provide a continuous up-to-date overview
of AI in radiology products, we created and maintain the
website www.aiforradiology.com. It will become clear in the
next few years how the AI for radiologymarket evolves, grows,
and matures. Future research may thus entail an updated
analysis to discover what and how the landscape has changed.
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